Melpomeni Fani

University Hospital Basel

Switzerland

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Pharmacology

50%

Pharmacotherapy

70%

Radiopharmaceutical Chemistry

80%

Targeted Therapy

50%

Preclinical Imaging

30%

Radiobiology

20%

Endocrinology

20%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles10

First-in-human administration of terbium-161-labelled somatostatin receptor subtype 2 antagonist ([161Tb]Tb-DOTA-LM3) in a patient with a metastatic neuroendocrine tumour of the ileum

Article Link

Year:

2024

In-vivo inhibition of neutral endopeptidase 1 results in higher absorbed tumor doses of [177Lu]Lu-PP-F11N in humans: the lumed phase 0b study

Article Link

Year:

2024

Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study

Article Link

Year:

2024

Development of the 99mTc-Labelled SST2 Antagonist TECANT-1 for a First-in-Man Multicentre Clinical Study

Article Link

Year:

2023

Development of a New Class of CXCR4-Targeting Radioligands Based on the Endogenous Antagonist EPI-X4 for Oncological Applications

Article Link

Year:

2023

Comparison of 99mTc radiolabeled somatostatin antagonist with [68 Ga]Ga-DOTA-TATE in a patient with advanced neuroendocrine tumor.

Article Link

Year:

2023

Early response monitoring during [177Lu]Lu-PSMA I&T therapy with quantitated SPECT/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study

Article Link

Year:

2023

61Cu-Labeled Radiotracers: Alternative or Choice?

Article Link

Year:

2023

CUDC-907, a dual PI3K/histone deacetylase inhibitor, increases meta-iodobenzylguanidine uptake (123/131I-mIBG) in vitro and in vivo: a promising candidate for advancing theranostics in neuroendocrine tumors

Article Link

Year:

2023

Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptides

Article Link

Year:

2023

Collaborators3

Jan Münch

GERMANY

Piotr Garnuszek

associate professor

National Centre for Nuclear Research

POLAND

Irene Virgolini

AUSTRIA

How do I reach out?

Meet Kite AI

Melpomeni Fani

How do I reach out?

Contact this professor

Research Interests

Ask ApplyKite AI

Articles10

First-in-human administration of terbium-161-labelled somatostatin receptor subtype 2 antagonist ([161Tb]Tb-DOTA-LM3) in a patient with a metastatic neuroendocrine tumour of the ileum

In-vivo inhibition of neutral endopeptidase 1 results in higher absorbed tumor doses of [177Lu]Lu-PP-F11N in humans: the lumed phase 0b study

Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study

Development of the <sup>99m</sup>Tc-Labelled SST<sub>2</sub> Antagonist TECANT-1 for a First-in-Man Multicentre Clinical Study

Development of a New Class of CXCR4-Targeting Radioligands Based on the Endogenous Antagonist EPI-X4 for Oncological Applications

Comparison of 99mTc radiolabeled somatostatin antagonist with [<sup>68</sup> Ga]Ga-DOTA-TATE in a patient with advanced neuroendocrine tumor.

Early response monitoring during [177Lu]Lu-PSMA I&T therapy with quantitated SPECT/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study

<sup>61</sup>Cu-Labeled Radiotracers: Alternative or Choice?

CUDC-907, a dual PI3K/histone deacetylase inhibitor, increases meta-iodobenzylguanidine uptake (123/131I-mIBG) in vitro and in vivo: a promising candidate for advancing theranostics in neuroendocrine tumors

Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptides

Collaborators3

Jan Münch

Piotr Garnuszek

Irene Virgolini

How do I reach out?

Melpomeni Fani

How do I reach out?

Contact this professor

Research Interests

Ask ApplyKite AI

Articles10

First-in-human administration of terbium-161-labelled somatostatin receptor subtype 2 antagonist ([161Tb]Tb-DOTA-LM3) in a patient with a metastatic neuroendocrine tumour of the ileum

In-vivo inhibition of neutral endopeptidase 1 results in higher absorbed tumor doses of [177Lu]Lu-PP-F11N in humans: the lumed phase 0b study

Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study

Development of the <sup>99m</sup>Tc-Labelled SST<sub>2</sub> Antagonist TECANT-1 for a First-in-Man Multicentre Clinical Study

Development of a New Class of CXCR4-Targeting Radioligands Based on the Endogenous Antagonist EPI-X4 for Oncological Applications

Comparison of 99mTc radiolabeled somatostatin antagonist with [<sup>68</sup> Ga]Ga-DOTA-TATE in a patient with advanced neuroendocrine tumor.

Early response monitoring during [177Lu]Lu-PSMA I&amp;T therapy with quantitated SPECT/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study

<sup>61</sup>Cu-Labeled Radiotracers: Alternative or Choice?

CUDC-907, a dual PI3K/histone deacetylase inhibitor, increases meta-iodobenzylguanidine uptake (123/131I-mIBG) in vitro and in vivo: a promising candidate for advancing theranostics in neuroendocrine tumors

Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptides

Collaborators3

Jan Münch

Piotr Garnuszek

Irene Virgolini

How do I reach out?

Early response monitoring during [177Lu]Lu-PSMA I&T therapy with quantitated SPECT/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study